» Articles » PMID: 24898537

Odanacatib Treatment Affects Trabecular and Cortical Bone in the Femur of Postmenopausal Women: Results of a Two-year Placebo-controlled Trial

Overview
Date 2014 Jun 6
PMID 24898537
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Odanacatib, a selective cathepsin K inhibitor, increases areal bone mineral density (aBMD) at the spine and hip of postmenopausal women. To gain additional insight into the effects on trabecular and cortical bone, we analyzed quantitative computed tomography (QCT) data of postmenopausal women treated with odanacatib using Medical Image Analysis Framework (MIAF; Institute of Medical Physics, University of Erlangen, Erlangen, Germany). This international, randomized, double-blind, placebo-controlled, 2-year, phase 3 trial enrolled 214 postmenopausal women (mean age 64 years) with low aBMD. Subjects were randomized to odanacatib 50 mg weekly (ODN) or placebo (PBO); all participants received calcium and vitamin D. Hip QCT scans at 24 months were available for 158 women (ODN: n = 78 women; PBO: n = 80 women). There were consistent and significant differential treatment effects (ODN-PBO) for total hip integral (5.4%), trabecular volumetric BMD (vBMD) (12.2%), and cortical vBMD (2.5%) at 24 months. There was no significant differential treatment effect on integral bone volume. Results for bone mineral content (BMC) closely matched those for vBMD for integral and trabecular compartments. However, with small but mostly significant differential increases in cortical volume (1.0% to 1.3%) and thickness (1.4% to 1.9%), the percentage cortical BMC increases were numerically larger than those of vBMD. With a total hip BMC differential treatment effect (ODN-PBO) of nearly 1000 mg, the proportions of BMC attributed to cortical gain were 45%, 44%, 52%, and 40% for the total, neck, trochanter, and intertrochanter subregions, respectively. In postmenopausal women treated for 2 years, odanacatib improved integral, trabecular, and cortical vBMD and BMC at all femur regions relative to placebo when assessed by MIAF. Cortical volume and thickness increased significantly in all regions except the femoral neck. The increase in cortical volume and BMC paralleled the increase in cortical vBMD, demonstrating a consistent effect of ODN on cortical bone. Approximately one-half of the absolute BMC gain occurred in cortical bone.

Citing Articles

Efficacy and safety of odanacatib in the treatment of postmenopausal women with osteoporosis: a meta-analysis.

Li J, Qiu Q, Jiang S, Sun J, Pavel V, Li Y J Orthop Surg Res. 2024; 19(1):521.

PMID: 39210429 PMC: 11361187. DOI: 10.1186/s13018-024-05008-z.


Efficacy and safety of odanacatib for osteoporosis treatment: a systematic review and meta-analysis.

Chen R, Chen C, Geng B, Yang C, Xiao H, Yang F Arch Osteoporos. 2023; 18(1):67.

PMID: 37169994 DOI: 10.1007/s11657-023-01261-7.


Denosumab in Cementless Total Hip Arthroplasty: Multivariate Reanalysis of 3D Femoral Stem Migration and the Influence on Outliers.

Finnila S, Loyttyniemi E, Aro H JBMR Plus. 2022; 6(2):e10588.

PMID: 35229065 PMC: 8861983. DOI: 10.1002/jbm4.10588.


Bovine Milk Extracellular Vesicles Are Osteoprotective by Increasing Osteocyte Numbers and Targeting RANKL/OPG System in Experimental Models of Bone Loss.

Oliveira M, Pieters B, Guimaraes P, Duffles L, Heredia J, Silveira A Front Bioeng Biotechnol. 2020; 8:891.

PMID: 32850743 PMC: 7411003. DOI: 10.3389/fbioe.2020.00891.


Hip Fracture Discrimination Based on Statistical Multi-parametric Modeling (SMPM).

Carballido-Gamio J, Yu A, Wang L, Su Y, Burghardt A, Lang T Ann Biomed Eng. 2019; 47(11):2199-2212.

PMID: 31240508 PMC: 7012369. DOI: 10.1007/s10439-019-02298-x.